LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients
(PRLEAP.COM) Denver, CO - LegalView informed mesothelioma blog readers of a new scientific test that may offer early diagnosis of mesothelioma cancer. The diagnostic test is an effort between Rosetta Genomics Ltd. and the Columbia University Medical Center. The two organizations have completed the test that can determine between two similar forms of lung cancer. The research is being hailed as a breakthrough, especially for those suffering from mesothelioma cancer. Those who have mesothelioma cancer or who have lost a loved one to the disease can speak with a mesothelioma attorney and learn about the details of a potential mesothelioma lawsuit in which monetary compensation may be awarded.Mesothelioma is an incurable lung cancer that has been linked to the inhalation of asbestos fibers and dust. The cancer typically remains dormant within the body for years or even decades, and is often misdiagnosed because its symptoms are similar to other variations of lung cancer as well as other diseases. Individuals who have been affected by this condition can receive legal consultation and additional mesothelioma information by speaking with a mesothelioma lawyer.
For more information on this and other mesothelioma research, visit LegalView’s homepage at http://www.LegalView.com/. Readers will also find a vast array of legal resources ranging from information on rare diseases or on the latest news of controversial pharmaceutical drugs and U.S. Food and Drug Administration (FDA) recalls. Most recently, the FDA increased the labeling of a group of antibiotics - increasing the label to a black box warning, which is considered the strongest and harshest of the FDA’s labeling. Among the fluoroquinolone antibiotics are Cipro and Levaquin, the most commonly prescribed of this allegedly dangerous group of prescription drugs.
Cipro, also known as ciprofloxacin, is an antibiotic that was released in August 2000 from Bayer A.G. The antibiotic treats a multitude of bacterial infections but has been linked to several severe side effects, the most extreme being tendon rupture among patients. Specifically, patients who took the drug, whether short or long term, are subject to a high risk of Achilles tendonitis. The risk also affects individuals who took the drug anywhere from weeks before the tendon rupture to patients who may have taken the drug years prior to their tendon rupture. Individuals suffering from this condition are advised to seek legal counsel to learn about a potential Cipro class action lawsuit.
Levaquin, levofloxacin, similar to Cipro, treats several types of bacterial infections including gonorrhea, pneumonia, bronchitis, etc. The drug has also been subject to the black box labeling and the Levaquin warning includes the risk of tendon rupture among patients.
Contact Information
About This News Release
If you have any questions regarding information in these press releases please contact the organization listed in the press release. Issuers of press releases and not PR Leap are solely responsible for the accuracy of the content.